Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
Music
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/79/97/f6/7997f65e-bdc9-9b4b-1e2d-d87871c23b87/mza_3829520858617886114.png/600x600bb.jpg
MAP - Market Access Podcast
Dr. Stefan Walzer
99 episodes
8 hours ago
Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world. MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries. The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves. Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany). Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition. Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.
Show more...
Business
Health & Fitness,
Medicine,
Science
RSS
All content for MAP - Market Access Podcast is the property of Dr. Stefan Walzer and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world. MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries. The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves. Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany). Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition. Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.
Show more...
Business
Health & Fitness,
Medicine,
Science
Episodes (20/99)
MAP - Market Access Podcast
What Can Europe and the U.S. Learn from Each Other on Market Access, Anne Loos?
5 days ago
27 minutes 4 seconds

MAP - Market Access Podcast
Will AI and Living Reviews Define the Next Era of Health Policy, Anna Forsythe?
3 weeks ago
29 minutes 16 seconds

MAP - Market Access Podcast
Are We Undervaluing the Economic Power of Health, Dr. Malina Müller?
1 month ago
38 minutes 2 seconds

MAP - Market Access Podcast
How Should Pharma Respond to the New Reality of Market Access in Germany, Prof. Dr. Thomas Hammerschmidt?
1 month ago
34 minutes 19 seconds

MAP - Market Access Podcast
Do Swiss Reimbursement Reforms Open Doors—or Raise New Barriers, Petra Erni?
2 months ago
29 minutes 13 seconds

MAP - Market Access Podcast
The Startup Guide to Navigating Healthcare Reimbursement, Featuring Ron de Graaff (Repost)
2 months ago
33 minutes 56 seconds

MAP - Market Access Podcast
Europe vs. US: Who Leads the Future of Market Access, Dr. Doug Niven?
3 months ago
43 minutes 30 seconds

MAP - Market Access Podcast
What Does It Really Take to Master AMNOG in Today’s Market Access Landscape, Anja Pownell?
3 months ago
25 minutes 49 seconds

MAP - Market Access Podcast
Is Cross-Functional Alignment the Secret to Successful Market Access, Kasem Akhras?
4 months ago
38 minutes 29 seconds

MAP - Market Access Podcast
How Do You Unlock the Power of Statistics in Market Access, Necdet Gunsoy?
4 months ago
36 minutes 3 seconds

MAP - Market Access Podcast
How will AI shape the future of Market Access and Systematic Reviews, Jeffrey Johnson and Kevin Kallmes? (Repost)
5 months ago
34 minutes 9 seconds

MAP - Market Access Podcast
How Can Market Access Professionals Plan for Long-Term Success, Adrian Kielhorn?
5 months ago
38 minutes 13 seconds

MAP - Market Access Podcast
What Are the Biggest Challenges & Opportunities of JCA, Dr. Nick Leach?
6 months ago
35 minutes 42 seconds

MAP - Market Access Podcast
Are We Overlooking the Real Benefits of Medical Innovation, Dr. Ahmed Seddik?
6 months ago
33 minutes 42 seconds

MAP - Market Access Podcast
What Are the Biggest Challenges in Implementing AI in Pharma, Jan Kroschinski?
7 months ago
43 minutes 38 seconds

MAP - Market Access Podcast
How Can Startups Leverage Market Access to Attract Investors, Johan Olsson?
7 months ago
33 minutes 3 seconds

MAP - Market Access Podcast
How Are Data Privacy Laws Delaying Patient Access to New Treatments, Douglas Drake and Adam Skali?
8 months ago
34 minutes 58 seconds

MAP - Market Access Podcast
How Can Innovation Planning Transform Market Access Success, Dr. Kasia Hein-Peters?
8 months ago
33 minutes 27 seconds

MAP - Market Access Podcast
How does early Market Access bridge the gap between innovation and commercial success, Catherine Bacon?
9 months ago
31 minutes 42 seconds

MAP - Market Access Podcast
A Flourishing Career in Pharmaceutical Market Access: Which Skills Are Essential, Dipti Tankala? (Repost)
9 months ago
32 minutes 5 seconds

MAP - Market Access Podcast
Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world. MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries. The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves. Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany). Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition. Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.